img

Global Opioid Antagonist Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Opioid Antagonist Market Insights, Forecast to 2034

Global Opioid Antagonist market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Opioid Antagonist industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Opioid Antagonist market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Opioid Antagonist market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Indivior
Alkermes
Titan Pharmaceuticals
Opiant Pharmaceuticals
Hikma Pharmaceuticals
Orexo
Camurus
Acura Pharmaceuticals
Shionogi
BioDelivery Sciences International
Collegium Pharmaceutical
AstraZeneca
Segment by Type
Oral
Parenteral

Segment by Application


Hospitals
Clinics
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Opioid Antagonist plant distribution, commercial date of Opioid Antagonist, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Opioid Antagonist introduction, etc. Opioid Antagonist Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Opioid Antagonist
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Opioid Antagonist Product Introduction
1.2 Market by Type
1.2.1 Global Opioid Antagonist Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Parenteral
1.3 Market by Application
1.3.1 Global Opioid Antagonist Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Opioid Antagonist Sales Estimates and Forecasts 2018-2029
2.2 Global Opioid Antagonist Revenue by Region
2.2.1 Global Opioid Antagonist Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Opioid Antagonist Revenue by Region (2018-2024)
2.2.3 Global Opioid Antagonist Revenue by Region (2024-2029)
2.2.4 Global Opioid Antagonist Revenue Market Share by Region (2018-2029)
2.3 Global Opioid Antagonist Sales Estimates and Forecasts 2018-2029
2.4 Global Opioid Antagonist Sales by Region
2.4.1 Global Opioid Antagonist Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Opioid Antagonist Sales by Region (2018-2024)
2.4.3 Global Opioid Antagonist Sales by Region (2024-2029)
2.4.4 Global Opioid Antagonist Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Opioid Antagonist Sales by Manufacturers
3.1.1 Global Opioid Antagonist Sales by Manufacturers (2018-2024)
3.1.2 Global Opioid Antagonist Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Opioid Antagonist in 2022
3.2 Global Opioid Antagonist Revenue by Manufacturers
3.2.1 Global Opioid Antagonist Revenue by Manufacturers (2018-2024)
3.2.2 Global Opioid Antagonist Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Opioid Antagonist Revenue in 2022
3.3 Global Key Players of Opioid Antagonist, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Opioid Antagonist Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Opioid Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Opioid Antagonist, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Opioid Antagonist, Product Offered and Application
3.8 Global Key Manufacturers of Opioid Antagonist, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Opioid Antagonist Sales by Type
4.1.1 Global Opioid Antagonist Historical Sales by Type (2018-2024)
4.1.2 Global Opioid Antagonist Forecasted Sales by Type (2024-2029)
4.1.3 Global Opioid Antagonist Sales Market Share by Type (2018-2029)
4.2 Global Opioid Antagonist Revenue by Type
4.2.1 Global Opioid Antagonist Historical Revenue by Type (2018-2024)
4.2.2 Global Opioid Antagonist Forecasted Revenue by Type (2024-2029)
4.2.3 Global Opioid Antagonist Revenue Market Share by Type (2018-2029)
4.3 Global Opioid Antagonist Price by Type
4.3.1 Global Opioid Antagonist Price by Type (2018-2024)
4.3.2 Global Opioid Antagonist Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Opioid Antagonist Sales by Application
5.1.1 Global Opioid Antagonist Historical Sales by Application (2018-2024)
5.1.2 Global Opioid Antagonist Forecasted Sales by Application (2024-2029)
5.1.3 Global Opioid Antagonist Sales Market Share by Application (2018-2029)
5.2 Global Opioid Antagonist Revenue by Application
5.2.1 Global Opioid Antagonist Historical Revenue by Application (2018-2024)
5.2.2 Global Opioid Antagonist Forecasted Revenue by Application (2024-2029)
5.2.3 Global Opioid Antagonist Revenue Market Share by Application (2018-2029)
5.3 Global Opioid Antagonist Price by Application
5.3.1 Global Opioid Antagonist Price by Application (2018-2024)
5.3.2 Global Opioid Antagonist Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Opioid Antagonist Market Size by Type
6.1.1 US & Canada Opioid Antagonist Sales by Type (2018-2029)
6.1.2 US & Canada Opioid Antagonist Revenue by Type (2018-2029)
6.2 US & Canada Opioid Antagonist Market Size by Application
6.2.1 US & Canada Opioid Antagonist Sales by Application (2018-2029)
6.2.2 US & Canada Opioid Antagonist Revenue by Application (2018-2029)
6.3 US & Canada Opioid Antagonist Market Size by Country
6.3.1 US & Canada Opioid Antagonist Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Opioid Antagonist Sales by Country (2018-2029)
6.3.3 US & Canada Opioid Antagonist Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Opioid Antagonist Market Size by Type
7.1.1 Europe Opioid Antagonist Sales by Type (2018-2029)
7.1.2 Europe Opioid Antagonist Revenue by Type (2018-2029)
7.2 Europe Opioid Antagonist Market Size by Application
7.2.1 Europe Opioid Antagonist Sales by Application (2018-2029)
7.2.2 Europe Opioid Antagonist Revenue by Application (2018-2029)
7.3 Europe Opioid Antagonist Market Size by Country
7.3.1 Europe Opioid Antagonist Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Opioid Antagonist Sales by Country (2018-2029)
7.3.3 Europe Opioid Antagonist Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Opioid Antagonist Market Size
8.1.1 China Opioid Antagonist Sales (2018-2029)
8.1.2 China Opioid Antagonist Revenue (2018-2029)
8.2 China Opioid Antagonist Market Size by Application
8.2.1 China Opioid Antagonist Sales by Application (2018-2029)
8.2.2 China Opioid Antagonist Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Opioid Antagonist Market Size by Type
9.1.1 Asia Opioid Antagonist Sales by Type (2018-2029)
9.1.2 Asia Opioid Antagonist Revenue by Type (2018-2029)
9.2 Asia Opioid Antagonist Market Size by Application
9.2.1 Asia Opioid Antagonist Sales by Application (2018-2029)
9.2.2 Asia Opioid Antagonist Revenue by Application (2018-2029)
9.3 Asia Opioid Antagonist Sales by Region
9.3.1 Asia Opioid Antagonist Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Opioid Antagonist Revenue by Region (2018-2029)
9.3.3 Asia Opioid Antagonist Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Opioid Antagonist Market Size by Type
10.1.1 Middle East, Africa and Latin America Opioid Antagonist Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Opioid Antagonist Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Opioid Antagonist Market Size by Application
10.2.1 Middle East, Africa and Latin America Opioid Antagonist Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Opioid Antagonist Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Opioid Antagonist Sales by Country
10.3.1 Middle East, Africa and Latin America Opioid Antagonist Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Opioid Antagonist Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Opioid Antagonist Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Indivior
11.1.1 Indivior Company Information
11.1.2 Indivior Overview
11.1.3 Indivior Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Indivior Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Indivior Recent Developments
11.2 Alkermes
11.2.1 Alkermes Company Information
11.2.2 Alkermes Overview
11.2.3 Alkermes Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Alkermes Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Alkermes Recent Developments
11.3 Titan Pharmaceuticals
11.3.1 Titan Pharmaceuticals Company Information
11.3.2 Titan Pharmaceuticals Overview
11.3.3 Titan Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Titan Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Titan Pharmaceuticals Recent Developments
11.4 Opiant Pharmaceuticals
11.4.1 Opiant Pharmaceuticals Company Information
11.4.2 Opiant Pharmaceuticals Overview
11.4.3 Opiant Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Opiant Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Opiant Pharmaceuticals Recent Developments
11.5 Hikma Pharmaceuticals
11.5.1 Hikma Pharmaceuticals Company Information
11.5.2 Hikma Pharmaceuticals Overview
11.5.3 Hikma Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Hikma Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Hikma Pharmaceuticals Recent Developments
11.6 Orexo
11.6.1 Orexo Company Information
11.6.2 Orexo Overview
11.6.3 Orexo Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Orexo Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Orexo Recent Developments
11.7 Camurus
11.7.1 Camurus Company Information
11.7.2 Camurus Overview
11.7.3 Camurus Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Camurus Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Camurus Recent Developments
11.8 Acura Pharmaceuticals
11.8.1 Acura Pharmaceuticals Company Information
11.8.2 Acura Pharmaceuticals Overview
11.8.3 Acura Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Acura Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Acura Pharmaceuticals Recent Developments
11.9 Shionogi
11.9.1 Shionogi Company Information
11.9.2 Shionogi Overview
11.9.3 Shionogi Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Shionogi Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Shionogi Recent Developments
11.10 BioDelivery Sciences International
11.10.1 BioDelivery Sciences International Company Information
11.10.2 BioDelivery Sciences International Overview
11.10.3 BioDelivery Sciences International Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 BioDelivery Sciences International Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 BioDelivery Sciences International Recent Developments
11.11 Collegium Pharmaceutical
11.11.1 Collegium Pharmaceutical Company Information
11.11.2 Collegium Pharmaceutical Overview
11.11.3 Collegium Pharmaceutical Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Collegium Pharmaceutical Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Collegium Pharmaceutical Recent Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Company Information
11.12.2 AstraZeneca Overview
11.12.3 AstraZeneca Opioid Antagonist Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 AstraZeneca Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 AstraZeneca Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Opioid Antagonist Industry Chain Analysis
12.2 Opioid Antagonist Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Opioid Antagonist Production Mode & Process
12.4 Opioid Antagonist Sales and Marketing
12.4.1 Opioid Antagonist Sales Channels
12.4.2 Opioid Antagonist Distributors
12.5 Opioid Antagonist Customers
13 Market Dynamics
13.1 Opioid Antagonist Industry Trends
13.2 Opioid Antagonist Market Drivers
13.3 Opioid Antagonist Market Challenges
13.4 Opioid Antagonist Market Restraints
14 Key Findings in The Global Opioid Antagonist Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Opioid Antagonist Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Oral
Table 3. Major Manufacturers of Parenteral
Table 4. Global Opioid Antagonist Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Opioid Antagonist Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Opioid Antagonist Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Opioid Antagonist Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Opioid Antagonist Revenue Market Share by Region (2018-2024)
Table 9. Global Opioid Antagonist Revenue Market Share by Region (2024-2029)
Table 10. Global Opioid Antagonist Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Opioid Antagonist Sales by Region (2018-2024) & (K Units)
Table 12. Global Opioid Antagonist Sales by Region (2024-2029) & (K Units)
Table 13. Global Opioid Antagonist Sales Market Share by Region (2018-2024)
Table 14. Global Opioid Antagonist Sales Market Share by Region (2024-2029)
Table 15. Global Opioid Antagonist Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Opioid Antagonist Sales Share by Manufacturers (2018-2024)
Table 17. Global Opioid Antagonist Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Opioid Antagonist Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Opioid Antagonist, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Opioid Antagonist Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Opioid Antagonist Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Opioid Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid Antagonist as of 2022)
Table 23. Global Key Manufacturers of Opioid Antagonist, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Opioid Antagonist, Product Offered and Application
Table 25. Global Key Manufacturers of Opioid Antagonist, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Opioid Antagonist Sales by Type (2018-2024) & (K Units)
Table 28. Global Opioid Antagonist Sales by Type (2024-2029) & (K Units)
Table 29. Global Opioid Antagonist Sales Share by Type (2018-2024)
Table 30. Global Opioid Antagonist Sales Share by Type (2024-2029)
Table 31. Global Opioid Antagonist Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Opioid Antagonist Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Opioid Antagonist Revenue Share by Type (2018-2024)
Table 34. Global Opioid Antagonist Revenue Share by Type (2024-2029)
Table 35. Opioid Antagonist Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Opioid Antagonist Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Opioid Antagonist Sales by Application (2018-2024) & (K Units)
Table 38. Global Opioid Antagonist Sales by Application (2024-2029) & (K Units)
Table 39. Global Opioid Antagonist Sales Share by Application (2018-2024)
Table 40. Global Opioid Antagonist Sales Share by Application (2024-2029)
Table 41. Global Opioid Antagonist Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Opioid Antagonist Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Opioid Antagonist Revenue Share by Application (2018-2024)
Table 44. Global Opioid Antagonist Revenue Share by Application (2024-2029)
Table 45. Opioid Antagonist Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Opioid Antagonist Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Opioid Antagonist Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Opioid Antagonist Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Opioid Antagonist Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Opioid Antagonist Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Opioid Antagonist Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Opioid Antagonist Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Opioid Antagonist Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Opioid Antagonist Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Opioid Antagonist Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Opioid Antagonist Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Opioid Antagonist Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Opioid Antagonist Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Opioid Antagonist Sales by Country (2024-2029) & (K Units)
Table 60. Europe Opioid Antagonist Sales by Type (2018-2024) & (K Units)
Table 61. Europe Opioid Antagonist Sales by Type (2024-2029) & (K Units)
Table 62. Europe Opioid Antagonist Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Opioid Antagonist Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Opioid Antagonist Sales by Application (2018-2024) & (K Units)
Table 65. Europe Opioid Antagonist Sales by Application (2024-2029) & (K Units)
Table 66. Europe Opioid Antagonist Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Opioid Antagonist Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Opioid Antagonist Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Opioid Antagonist Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Opioid Antagonist Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Opioid Antagonist Sales by Country (2018-2024) & (K Units)
Table 72. Europe Opioid Antagonist Sales by Country (2024-2029) & (K Units)
Table 73. China Opioid Antagonist Sales by Type (2018-2024) & (K Units)
Table 74. China Opioid Antagonist Sales by Type (2024-2029) & (K Units)
Table 75. China Opioid Antagonist Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Opioid Antagonist Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Opioid Antagonist Sales by Application (2018-2024) & (K Units)
Table 78. China Opioid Antagonist Sales by Application (2024-2029) & (K Units)
Table 79. China Opioid Antagonist Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Opioid Antagonist Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Opioid Antagonist Sales by Type (2018-2024) & (K Units)
Table 82. Asia Opioid Antagonist Sales by Type (2024-2029) & (K Units)
Table 83. Asia Opioid Antagonist Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Opioid Antagonist Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Opioid Antagonist Sales by Application (2018-2024) & (K Units)
Table 86. Asia Opioid Antagonist Sales by Application (2024-2029) & (K Units)
Table 87. Asia Opioid Antagonist Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Opioid Antagonist Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Opioid Antagonist Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Opioid Antagonist Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Opioid Antagonist Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Opioid Antagonist Sales by Region (2018-2024) & (K Units)
Table 93. Asia Opioid Antagonist Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Opioid Antagonist Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Opioid Antagonist Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Opioid Antagonist Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Opioid Antagonist Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Opioid Antagonist Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Opioid Antagonist Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Opioid Antagonist Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Opioid Antagonist Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Opioid Antagonist Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Opioid Antagonist Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Opioid Antagonist Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Opioid Antagonist Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Opioid Antagonist Sales by Country (2024-2029) & (K Units)
Table 107. Indivior Company Information
Table 108. Indivior Description and Major Businesses
Table 109. Indivior Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Indivior Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Indivior Recent Developments
Table 112. Alkermes Company Information
Table 113. Alkermes Description and Major Businesses
Table 114. Alkermes Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Alkermes Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Alkermes Recent Developments
Table 117. Titan Pharmaceuticals Company Information
Table 118. Titan Pharmaceuticals Description and Major Businesses
Table 119. Titan Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Titan Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Titan Pharmaceuticals Recent Developments
Table 122. Opiant Pharmaceuticals Company Information
Table 123. Opiant Pharmaceuticals Description and Major Businesses
Table 124. Opiant Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Opiant Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Opiant Pharmaceuticals Recent Developments
Table 127. Hikma Pharmaceuticals Company Information
Table 128. Hikma Pharmaceuticals Description and Major Businesses
Table 129. Hikma Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Hikma Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Hikma Pharmaceuticals Recent Developments
Table 132. Orexo Company Information
Table 133. Orexo Description and Major Businesses
Table 134. Orexo Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Orexo Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Orexo Recent Developments
Table 137. Camurus Company Information
Table 138. Camurus Description and Major Businesses
Table 139. Camurus Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Camurus Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Camurus Recent Developments
Table 142. Acura Pharmaceuticals Company Information
Table 143. Acura Pharmaceuticals Description and Major Businesses
Table 144. Acura Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Acura Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Acura Pharmaceuticals Recent Developments
Table 147. Shionogi Company Information
Table 148. Shionogi Description and Major Businesses
Table 149. Shionogi Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Shionogi Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Shionogi Recent Developments
Table 152. BioDelivery Sciences International Company Information
Table 153. BioDelivery Sciences International Description and Major Businesses
Table 154. BioDelivery Sciences International Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. BioDelivery Sciences International Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. BioDelivery Sciences International Recent Developments
Table 157. Collegium Pharmaceutical Company Information
Table 158. Collegium Pharmaceutical Description and Major Businesses
Table 159. Collegium Pharmaceutical Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Collegium Pharmaceutical Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Collegium Pharmaceutical Recent Developments
Table 162. AstraZeneca Company Information
Table 163. AstraZeneca Description and Major Businesses
Table 164. AstraZeneca Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. AstraZeneca Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. AstraZeneca Recent Developments
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. Opioid Antagonist Distributors List
Table 170. Opioid Antagonist Customers List
Table 171. Opioid Antagonist Market Trends
Table 172. Opioid Antagonist Market Drivers
Table 173. Opioid Antagonist Market Challenges
Table 174. Opioid Antagonist Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid Antagonist Product Picture
Figure 2. Global Opioid Antagonist Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Opioid Antagonist Market Share by Type in 2022 & 2029
Figure 4. Oral Product Picture
Figure 5. Parenteral Product Picture
Figure 6. Global Opioid Antagonist Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Opioid Antagonist Market Share by Application in 2022 & 2029
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Others
Figure 11. Opioid Antagonist Report Years Considered
Figure 12. Global Opioid Antagonist Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Opioid Antagonist Revenue 2018-2029 (US$ Million)
Figure 14. Global Opioid Antagonist Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 15. Global Opioid Antagonist Revenue Market Share by Region (2018-2029)
Figure 16. Global Opioid Antagonist Sales 2018-2029 ((K Units)
Figure 17. Global Opioid Antagonist Sales Market Share by Region (2018-2029)
Figure 18. US & Canada Opioid Antagonist Sales YoY (2018-2029) & (K Units)
Figure 19. US & Canada Opioid Antagonist Revenue YoY (2018-2029) & (US$ Million)
Figure 20. Europe Opioid Antagonist Sales YoY (2018-2029) & (K Units)
Figure 21. Europe Opioid Antagonist Revenue YoY (2018-2029) & (US$ Million)
Figure 22. China Opioid Antagonist Sales YoY (2018-2029) & (K Units)
Figure 23. China Opioid Antagonist Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Asia (excluding China) Opioid Antagonist Sales YoY (2018-2029) & (K Units)
Figure 25. Asia (excluding China) Opioid Antagonist Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Opioid Antagonist Sales YoY (2018-2029) & (K Units)
Figure 27. Middle East, Africa and Latin America Opioid Antagonist Revenue YoY (2018-2029) & (US$ Million)
Figure 28. The Opioid Antagonist Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 29. The Top 5 and 10 Largest Manufacturers of Opioid Antagonist in the World: Market Share by Opioid Antagonist Revenue in 2022
Figure 30. Global Opioid Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Opioid Antagonist Sales Market Share by Type (2018-2029)
Figure 32. Global Opioid Antagonist Revenue Market Share by Type (2018-2029)
Figure 33. Global Opioid Antagonist Sales Market Share by Application (2018-2029)
Figure 34. Global Opioid Antagonist Revenue Market Share by Application (2018-2029)
Figure 35. US & Canada Opioid Antagonist Sales Market Share by Type (2018-2029)
Figure 36. US & Canada Opioid Antagonist Revenue Market Share by Type (2018-2029)
Figure 37. US & Canada Opioid Antagonist Sales Market Share by Application (2018-2029)
Figure 38. US & Canada Opioid Antagonist Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Opioid Antagonist Revenue Share by Country (2018-2029)
Figure 40. US & Canada Opioid Antagonist Sales Share by Country (2018-2029)
Figure 41. U.S. Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 42. Canada Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 43. Europe Opioid Antagonist Sales Market Share by Type (2018-2029)
Figure 44. Europe Opioid Antagonist Revenue Market Share by Type (2018-2029)
Figure 45. Europe Opioid Antagonist Sales Market Share by Application (2018-2029)
Figure 46. Europe Opioid Antagonist Revenue Market Share by Application (2018-2029)
Figure 47. Europe Opioid Antagonist Revenue Share by Country (2018-2029)
Figure 48. Europe Opioid Antagonist Sales Share by Country (2018-2029)
Figure 49. Germany Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 50. France Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 51. U.K. Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 52. Italy Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 53. Russia Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 54. China Opioid Antagonist Sales Market Share by Type (2018-2029)
Figure 55. China Opioid Antagonist Revenue Market Share by Type (2018-2029)
Figure 56. China Opioid Antagonist Sales Market Share by Application (2018-2029)
Figure 57. China Opioid Antagonist Revenue Market Share by Application (2018-2029)
Figure 58. Asia Opioid Antagonist Sales Market Share by Type (2018-2029)
Figure 59. Asia Opioid Antagonist Revenue Market Share by Type (2018-2029)
Figure 60. Asia Opioid Antagonist Sales Market Share by Application (2018-2029)
Figure 61. Asia Opioid Antagonist Revenue Market Share by Application (2018-2029)
Figure 62. Asia Opioid Antagonist Revenue Share by Region (2018-2029)
Figure 63. Asia Opioid Antagonist Sales Share by Region (2018-2029)
Figure 64. Japan Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 65. South Korea Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 66. China Taiwan Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 67. Southeast Asia Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 68. India Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Opioid Antagonist Sales Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Opioid Antagonist Revenue Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Opioid Antagonist Sales Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Opioid Antagonist Revenue Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Opioid Antagonist Revenue Share by Country (2018-2029)
Figure 74. Middle East, Africa and Latin America Opioid Antagonist Sales Share by Country (2018-2029)
Figure 75. Brazil Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 76. Mexico Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 77. Turkey Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 78. Israel Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 79. GCC Countries Opioid Antagonist Revenue (2018-2029) & (US$ Million)
Figure 80. Opioid Antagonist Value Chain
Figure 81. Opioid Antagonist Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries